What Happens When You Add Mosunetuzumab + Polatuzumab to CAR‑T (axi‑cel)? | Jay Spiegel, MD

New SEQUOIA Trial Results Shake Up First‑Line CLL Care! | Amit Agarwal, MD, PhD

New SEQUOIA Trial Results Shake Up First‑Line CLL Care! | Amit Agarwal, MD, PhD

Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD

Non-Covalent vs Covalent BTK Inhibitors: What’s Best of Patients | Jennifer Woyach, MD

SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD

SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD

Is the Blexi‑Ven Combo Safe and Effective? | Jenny O'Nions, MD

Is the Blexi‑Ven Combo Safe and Effective? | Jenny O'Nions, MD

Is Time-Limited Therapy the Future for CLL? | Romain Guieze, MD

Is Time-Limited Therapy the Future for CLL? | Romain Guieze, MD

Checkpoint Inhibitors Show High Response in Hard-to-Treat Lymphoma | Vincent Camus, MD, PhD

Sonrotoclax Could Be a Game‑Changer for MCL? | Amit Agarwal, MD, PhD

Is Rocbrutinib a New Option for CLL Patients? Phase 1 Trial Updates | Jennifer Woyach, MD

Is Rocbrutinib a New Option for CLL Patients? Phase 1 Trial Updates | Jennifer Woyach, MD

Is 1-Year Therapy Just as Effective as Multiple Years? | Othman Al-Sawaf, MD

Is 1-Year Therapy Just as Effective as Multiple Years? | Othman Al-Sawaf, MD

New Drug Combo for B-Cell Lymphoma: How Effective Is It? | Babis Andreadis, MD

CAR-T Cell Therapy: What Lymphoma Patients Need to Know | Fabio Efficace, PhD